220 related articles for article (PubMed ID: 27587008)
1. Modeling the functional state of the reverse transcriptase of hepatitis B virus and its application to probing drug-protein interaction.
Xu X; Thai H; Kitrinos KM; Xia G; Gaggar A; Paulson M; Ganova-Raeva L; Khudyakov Y; Lara J
BMC Bioinformatics; 2016 Aug; 17 Suppl 8(Suppl 8):280. PubMed ID: 27587008
[TBL] [Abstract][Full Text] [Related]
2. Variability in the Responses of Hepatitis B Virus D-Subgenotypes to Antiviral Therapy: Designing Pan-D-Subgenotypic Reverse Transcriptase Inhibitors.
Khatun M; Kumar K; Baidya A; Mondal RK; Baszczyňski O; Kalčic F; Banerjee S; Dhali GK; Das K; Chowdhury A; Janeba Z; Chakrabarti S; Datta S
J Virol; 2022 Jan; 96(2):e0180021. PubMed ID: 34730399
[TBL] [Abstract][Full Text] [Related]
3. Complex genetic encoding of the hepatitis B virus on-drug persistence.
Thai H; Lara J; Xu X; Kitrinos K; Gaggar A; Chan HLY; Xia GL; Ganova-Raeva L; Khudyakov Y
Sci Rep; 2020 Sep; 10(1):15574. PubMed ID: 32968103
[TBL] [Abstract][Full Text] [Related]
4. Differential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virus.
van Hemert FJ; Berkhout B; Zaaijer HL
PLoS One; 2014; 9(9):e106324. PubMed ID: 25180507
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.
Walsh AW; Langley DR; Colonno RJ; Tenney DJ
PLoS One; 2010 Feb; 5(2):e9195. PubMed ID: 20169198
[TBL] [Abstract][Full Text] [Related]
6. Distinctive HBV Replication Capacity and Susceptibility to Tenofovir Induced by a Polymerase Point Mutation in Hepatoma Cell Lines and Primary Human Hepatocytes.
Lee AR; Cho JY; Kim JC; Dezhbord M; Choo SY; Ahn CH; Kim NY; Shin JJ; Park S; Park ES; Won J; Kim DS; Lee JH; Kim KH
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562603
[TBL] [Abstract][Full Text] [Related]
7. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.
Nakajima S; Watashi K; Kato T; Muramatsu M; Wakita T; Tamura N; Hattori SI; Maeda K; Mitsuya H; Yasutake Y; Toyoda T
J Virol; 2021 Jul; 95(16):e0240120. PubMed ID: 34076480
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development.
Clark DN; Hu J
Antiviral Res; 2015 Nov; 123():132-7. PubMed ID: 26408354
[TBL] [Abstract][Full Text] [Related]
10. HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy.
Banerjee P; Chakraborty A; Mondal RK; Khatun M; Datta S; Das K; Pandit P; Mukherjee S; Banerjee S; Ghosh S; Chakrabarti S; Chowdhury A; Datta S
Sci Rep; 2017 Mar; 7():44742. PubMed ID: 28303969
[TBL] [Abstract][Full Text] [Related]
11. Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine.
Jones SA; Murakami E; Delaney W; Furman P; Hu J
Antimicrob Agents Chemother; 2013 Sep; 57(9):4181-9. PubMed ID: 23774432
[TBL] [Abstract][Full Text] [Related]
12. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of Adefovir, Tenofovir and Entecavir Resistance: Molecular Modeling Studies of How A Novel Anti-HBV Agent (FMCA) Can Overcome the Drug Resistance.
Rawal RK; Konreddy AK; Chu CK
Curr Med Chem; 2015; 22(34):3922-32. PubMed ID: 26336997
[TBL] [Abstract][Full Text] [Related]
14. Reverse transcriptase activity of hepatitis B virus (HBV) DNA polymerase within core capsid: interaction with deoxynucleoside triphosphates and anti-HBV L-deoxynucleoside analog triphosphates.
Lam W; Li Y; Liou JY; Dutschman GE; Cheng YC
Mol Pharmacol; 2004 Feb; 65(2):400-6. PubMed ID: 14742682
[TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
[TBL] [Abstract][Full Text] [Related]
16. Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.
Zhu Y; Curtis M; Qi X; Miller MD; Borroto-Esoda K
Antivir Chem Chemother; 2009; 19(4):165-76. PubMed ID: 19374144
[TBL] [Abstract][Full Text] [Related]
17. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
Lavocat F; Dény P; Pichoud C; Al Hawajri N; Kitrinos K; Borroto-Esoda K; Zoulim F
J Hepatol; 2013 Oct; 59(4):684-95. PubMed ID: 23742912
[TBL] [Abstract][Full Text] [Related]
18. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
Sheldon J; Camino N; Rodés B; Bartholomeusz A; Kuiper M; Tacke F; Núñez M; Mauss S; Lutz T; Klausen G; Locarnini S; Soriano V
Antivir Ther; 2005; 10(6):727-34. PubMed ID: 16218172
[TBL] [Abstract][Full Text] [Related]
19. Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: A case report and review of the literature.
Cho WH; Lee HJ; Bang KB; Kim SB; Song IH
World J Gastroenterol; 2018 May; 24(17):1919-1924. PubMed ID: 29740207
[TBL] [Abstract][Full Text] [Related]
20. Different Variants in Reverse Transcriptase Domain Determined by Ultra-deep Sequencing in Treatment-naïve and Treated Indonesian Patients Infected with Hepatitis B Virus.
Wasityastuti W; Yano Y; Widasari DI; Yamani LN; Ratnasari N; Heriyanto DS; Okada R; Tanahashi T; Murakami Y; Azuma T; Hayashi Y
Kobe J Med Sci; 2016 Jun; 62(1):E1-8. PubMed ID: 27492206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
